Virobay’s oral inhibitors VBY-036 (phase I, neuropathic pain) and VBY-891 (phase II, psoriasis) exhibit tissue-specific targeting, with the latter favoring skin CTSS modulation, alongside preclinical VBY-825 for neuropathic pain and Alzheimer’s disease (90). Here, CTSS is linked to psoriasis.